Nexium Control overview

Nexium Control Range

The UK’s No 1 for 24-hour heartburn protection1

Unlike antacids and alginates that treat the symptoms of heartburn, Nexium Control tackles the cause by targeting acid directly at the source providing long-lasting protection.

For news, updates and access to more resources and webinars please register now to be on our mailing list.

Register now

Nexium Control – Clinically proven protection for frequent heartburn

Tooth icon

Long lasting protection

With just one pill a day Nexium Control provides up to 24 hour protection for frequent heartburn sufferers.

Visual of 8 out of 10 people

Clinically proven

8 out of 10 people reported first resolution within the first week of treatment with Nexium Control.

Visual for 4 out of 5 nights heartburn free

Nighttime relief

4 out of 5 nights were heartburn free for patients using Nexium Control..

Nexium Control – Your first line recommendation for frequent heartburn

  • Frequency is key

    Dentine hypersensitivity recurrence cycle and management goals

    A key question for heartburn sufferers

    Suffering more than once per week with heartburn is classed as frequent heartburn.

    Regardless of its severity, frequent heartburn makes the oesophagus sensitive to acid such that it does not take a lot to trigger burning pain

    Ask your patients ‘How often do you suffer from heartburn each week?’

    Learn more about how the frequency of heartburn may impact treatment recommendations by clicking here.

  • 24-hour heartburn protection

    Visual of proton pump in stomach

    Break the cycle of short-term heartburn relief with Nexium Control

    Nexium Control is a proton pump inhibitor (PPI) containing 20mg esomeprazole.

    It works by reducing the production of acid in the stomach, providing up to 24 hour protection from heartburn.

    Antacids and alginates only offer short-acting relief from the pain of occasional heartburn until the stomach empties. At this point more acid is produced and the cycle starts again.

    Nexium Control can break the cycle of short-acting relief by reducing the production of stomach acid for up to 24-hours. It treats the cause and symptoms of heartburn, allowing time for the oesophagus to recover from the acid irritation.

      Duration of treatment Mode of action
    Antacids 1-3 hours Neutralises acid content in stomach. Repeated dosing necessary for newly secreted acid.
    Alginates Up to 4 hours Forms a raft on top of stomach contents to prevent escape through sphincter. Repeated dosing necessary for newly secreted acid.
    H2 blockers Up to 12 hours Blocks one of the 3 signals that stimulate acid production. Intermediate duration relief.
    PPI’s e.g. esomeprazole Up to 24 hours Acts on proton pump to reduce acid production. The lack of acid leaking from the stomach gives the oesophagus a ‘holiday’ from acid.

    Find out more about the science behind Nexium control

  • Helping to restore quality of life for sufferers

    Graph of quality of life impacts of frequent heartburn

    Nexium Control helps restore frequent heartburn sufferers’ quality of life

    Frequent heartburn can cause significant disruption to people’s lives, forcing them to avoid certain foods or making it difficult to get a good night’s sleep.

    Research has shown that within just 2 weeks of treatment with esomeprazole, the active ingredient in Nexium Control, the impact on quality of life by heartburn can be significantly improved or normalised.

    Improvements in scores were observed in nearly every quality-of-life parameter measured, including:2

    • Social functioning
    • Vitality
    • Activities affected by emotional or physical health
    • Pain
  • First line treatment for frequent heartburn

    NICE guidelines recommend PPI’s, such as Nexium Control, as first line treatment for frequent heartburn3

  • Find out more about frequent heartburn from a sufferer

    Find out more about the impact of frequent heartburn in this video featuring a patient who also shares how Nexium Control has helped to provide him with relief.

Find out more about frequent heartburn

Explore videos, product guides and other resources to support you and your team when recommending Nexium Control for frequent heartburn. Click here

Recommend Nexium Control for your patients with frequent heartburn

Nexium Control tablets pack

Nexium Control 20mg Gastro-Resistant Tablets (Esomeprazole)

Nexium Control 7 tablet pack is an ideal trial pack with one-week supply. Nexium Control 14 tablet pack offers the same protection and offers a 2-week treatment course.

Pack of Nexium Control 28 tablet capsules

NEW Nexium Control 28 tablet pack

Offers value and convenience for patients with frequent heartburn who have used esomeprazole successfully before.

Nexium Control capsules pack shot

Nexium Control 20mg Gastro-Resistant Capsules (Esomeprazole)

Easy-to swallow mini capsules – 53% smaller than tablet* in a portable bottle. Complete 14-day treatment course.

*based on volume

Product Information

Nexium Control 20 mg gastro‑resistant tablets and hard capsules. Esomeprazole. Indications: The short‑term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: The recommended dose is 20 mg esomeprazole (one tablet or capsule) per day. It might be necessary to take the tablets or capsules for 2‑3 consecutive days to achieve improvement of symptoms. The duration of treatment is up to 2 weeks. Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir. Warnings and precautions: Patients should be instructed to consult a doctor if: They have significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis. They have had previous gastric ulcer or gastrointestinal surgery. They have been on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks. They have jaundice or severe liver disease. They are aged over 55 years with new or recently changed symptoms. Patients with long‑term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals. Patients over 55 years taking any non‑prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor. Patients should not take Nexium Control as a long term preventive medicinal product. Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile. Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test. Co‑administration of esomeprazole with atazanavir is not recommended. If the combination of atazanavir with a PPI is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir. Esomeprazole 20 mg should not be exceeded. Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with medicinal products metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole although the clinical relevance of this interaction is uncertain. The use of esomeprazole with clopidogrel should be discouraged. Patients should not take another PPI or H2 antagonist concomitantly. Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of PPI treatment. Proton pump inhibitors are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Nexium Control. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors. This medicinal product contains sugar spheres (sucrose). Patients with rare hereditary problems of fructose intolerance, glucose‑galactose malabsorption or sucrase‑isomaltase insufficiency should not take this medicinal product. Side effects: See SPC for full details. Common: headache, abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash urticaria. Rare: leukopenia, thrombocytopenia, hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock, hyponatraemia, agitation, confusion, depression, taste disturbance, blurred vision, bronchospasm, stomatitis, gastrointestinal candidiasis, hepatitis with or without jaundice, alopecia, photosensitivity, arthralgia, myalgia, malaise, increased sweating. Very rare: agranulocytosis, pancytopenia, aggression, hallucinations, hepatic failure, hepatic encephalopathy in patients with pre-existing liver disease, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), muscular weakness, interstitial nephritis, gynaecomastia. Not known: hypomagnesaemia; severe hypomagnesaemia can correlate with hypocalcaemia; hypomagnesaemia may also result in hypokalaemia, microscopic colitis, subacute cutaneous lupus erythematosus SCLE. Legal category: GSL(7 and 14 pack) and P (28 pack). Product licence number: PLGB 44673/0221 and PLGB 44673/0222. MAH: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, Brentford, TW8 9GS RRP: Pack of 7 tablets RRP £6.99, pack of 14 tablets RRP £11.99, pack of 28 tablets RRP£21.99. Pack of 14 capsules RRP £12.99. The prices include VAT. Text prepared: May 2021

Nexium Control – the UK’s No 1 for 24-hour heartburn protection.1

Icon of stomach

Heartburn

Find out more about frequent heartburn including a profile of a patient who may suffer from the condition.

FIND OUT MORE

Man watching webinar

Webinars & Events

Register now to access a range of webinars and education modules online.

Register now

Icon of book

Educational resources

Access educational resources to support your team’s understanding of heartburn and its management.

FIND OUT MORE